<DOC>
	<DOCNO>NCT01095562</DOCNO>
	<brief_summary>This efficacy safety study evaluate experimental treatment cognitive deficit adult schizophrenia .</brief_summary>
	<brief_title>Safety Efficacy Study Cognitive Deficits Adult Subjects With Schizophrenia</brief_title>
	<detailed_description>This Phase 2 study design evaluate efficacy safety ABT-126 approximately 210 adult schizophrenia . Subjects randomize one three treatment group ( ABT-126 Dose 1 , ABT-126 Dose 2 placebo ) 12-week Treatment Period . The purpose research study find whether ABT-126 compare placebo improve cognition side effect ABT-126 may cause . Cognition way person think , include ability like pay attention , focus , remember thing , solve problem . Acronyms list Outcomes and/or Eligibility section study define : • MCCB : Measurement Treatment Research Improve Cognition Schizophrenia ( MATRICS ) Consensus Cognitive Battery • UPSA-2 : University California San Diego ( UCSD ) Performance-Based Skills Assessment-2 • CANTAB : Cambridge Neuropsychological Test Automated Battery • PANSS : Positive Negative Syndrome Scale • NSA-16 : Negative Symptom Assessment-16 • CGI-S : Clinical Global Impression - Severity</detailed_description>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Cognition Disorders</mesh_term>
	<criteria>Inclusion Criteria Has current DSMIVTR diagnosis schizophrenia confirm MiniInternational Neuropsychiatric Interview . Is clinically stable receive antipsychotic therapy one two atypical antipsychotic medication : lack hospitalization 4 month Initial Screening Visit ; take antipsychotic medication ( ) least 8 week prior Day 1 visit ; core positive symptom PANSS bad moderate severity throughout Screening Period least 4 week . Has diagnose treat schizophrenia least 2 year prior Initial Screening Visit . Has continuity psychiatric care ( e.g. , mental health system , clinic physician ) least 6 month prior Initial Screening Visit . Has identify responsible contact person ( e.g. , family member , social worker , case worker , nurse ) provide support subject ensure compliance protocol requirement . Exclusion Criteria Has valid current past diagnosis schizoaffective disorder , bipolar disorder , manic episode , dementia , posttraumatic stress disorder , obsessive compulsive disorder , current major depressive episode . Has history substance abuse ( exclude nicotine tobacco product ) alcohol abuse within 6 month prior Screening Visit ; substance dependence disorder ( exclude nicotine tobacco product ) remit least 1 year prior Initial Screening Visit . Is take medication extrapyramidal symptom time Initial Screening Visit Day 1 Visit . Is take antidepressant exclude , include tricyclic antidepressant monoamine oxidase inhibitor , time 8 week prior Day 1 Visit . Has significant suicidal ideation Initial Screening Visit . Has suicide attempt within 1 year prior Day 1 Visit . Has participate another trial utilize MATRICS Consensus Cognitive Battery ( MCCB ) UCSD PerformanceBased Skills Assessment ( UPSA ) ( version ) within 6 month prior Initial Screening Visit . Is currently enrol form cognitive remediation training .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>January 2013</verification_date>
</DOC>